TMDX Company Profile and Key Details

TMDX has shown sold momentum, gaining 5.4% over the past week and 20.66% over the past quarter, though year-to-date performance is up 16.67%. Short-term trend indicators are bearishly aligned (SMA20 0.42%, SMA50 1.3%, SMA200 7.31%). The stock’s 14-day RSI is 50.39 (neutral), while the ATR of 7.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.74% below its high and over 116.79% above its low. Average 10-day trading volume of 2.23 million shares is significantly above the 3-month average of 1.11 million, indicating heightened recent market interest.

Wall Street analysts project EPS growth of -1.06% annually over the next five years. The latest quarter delivered EPS of $0.30. The next quarter is forecast at $0.66. Next year's EPS is expected at $44.85. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 11 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $175.00 to $85.00. The high target offers 140.05% upside. The low target suggests 16.6% downside. The mean target is $140.92. This offers 93.31% upside. TransMedics Group, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by -51.61%. The prior quarter beat by 39.02%. Over the last six quarters, Apple has recorded several small beats. These include -13.64% in February 27, 2025.

TransMedics Group, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.09. This means the shares are trading below this model’s fair value.

TransMedics Group, Inc. (NASDAQ:TMDX) closed at $72.90 USD, losing -$0.02 (-0.03%) from the previous close of $72.92. The stock is currently within 5% of its 52-week low $70.00 and $156.00. With a market capitalization of about $2.52 billion, TransMedics Group, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.06). Key stats such as the average daily volume over the past year has been around 1.07 million shares, trading with heavier-than-usual volume. Headquartered in Andover, MA, TransMedics Group, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Waleed H. Hassanein, the company employs approximately 728 people and listed since May 02, 2019. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

TransMedics Group, Inc. has 34.09 million shares outstanding. The public float is 32.96 million shares, elevated short interest at 41.68% of float. This equals 8.27 million shares. The short ratio is 7.15 days. Institutional investors hold 114.36% of the float. Insiders own 3.3%. Hassanein Waleed H holds 495.01 thousand shares, TOBIN JAMES R has 173.15 thousand shares and Khayal Tamer I has 36.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 23.80 thousand shares across 9 transactions.

TransMedics Group, Inc. trades at a P/E ratio of 14.51, slightly below the S&P 500 average, with a price-to-sales ratio of 3.94 and a price-to-book ratio of 5.05 trading at moderately above to book value. The P/FCF stands at 16.57, also below market averages.

Our AI price prediction model suggests that TransMedics Group, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.46%, with price expected at $78.34 by May 20, 2026, within a range of $69.40 to $87.31 3-Month Outlook: Projected rise of 29.19%, reaching $94.18 by August 04, 2026, with a range of $83.56 to $105.29. 1-Year Outlook: Projected gain of 34.1%, with price at $97.76 by May 06, 2027, within a range of $86.25 to $107.84.

TransMedics Group, Inc. (NASDAQ:TMDX) shares are up 16.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows TransMedics Group, Inc. trading at a premium to the broader market with a P/E of 14.51. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $124.26, suggesting 70.45% upside. Our AI forecast model points to short-term strength (7.46% over two weeks), a medium-term rise (29.19% over three months), and a longer-term gain (34.1% over one year), with expected trading ranges indicating moderate volatility.